Accent Microcell Limited — Investor Meet, 21-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Accent Microcell reported increased revenue, EBITDA, and PAT for the financial results for the quarter and half-year ended March 31, 2026, driven by higher-margin premium products. Export revenue grew to 63%.

Unit 3 Phase 1 (premium excipients like CCS) is anticipated to start commercial production by end-June 2026, targeting 650-700 Rs/Kg realizations. Phase 2 (MCC) is planned for March 2027. The company's new pulp-based CMC technology is an Indian first.

Management expects blended profit margins to rise by 2-3 percentage points. Trading volumes will significantly decrease post-Phase 2. The outlook points to continued growth and margin expansion through strategic capacity additions.